Canada says warnings needed on bird flu drug Tamiflu

Canadian health authority Health Canada has requested that the manufacturer of the antiviral drug Tamiflu place warnings on it's labels of adverse effects.

Health Canada wants the Swiss pharma group Roche to place warnings of side-effects such as abnormal behaviour, including self-harm, on the drugs packaging.

According to Health Canada up to November 11th there have been 84 reports of patients having adverse effects when using Tamiflu and ten of those cases died, though no causal link has been established as yet.

Health Canada has said there have been 'international reports of hallucinations and abnormal behaviour, including self harm, in patients taking the antiviral drug Tamiflu'.

Health Canada says while the connection with the drug in these cases has not yet been proven, high fever or other complications of influenza can affect mental state, which in turn can lead to abnormal behaviour, and it will continue to monitor the safety of the drug.

The EU's Committee for Medicinal Products for Human Use (CHMP) has recently said there was no evidence to suggest a causal relation between the drug and mental or emotional disorders and that Tamiflu was not a health risk.

But concern over the drug's safety first occurred in the U.S. last October when it was claimed Tamiflu caused such symptoms, in particular in children.

Roche has issued a statement rejecting recent claims that the H5N1 bird flu virus was showing increased resistance to Tamiflu in some patients infected with it.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global experts gather in Brisbane for scientific meeting dedicated to influenza